NASDAQ: OBIOOrchestra Biomed Holdings Inc Stock
$8.72+1.02 (+13.25%)
Updated Sep 29, 2023
OBIO Price
$8.72
Fair Value Price
N/A
Market Cap
$311.69M
52 Week Low
$4.85
52 Week High
$23.39
P/E
N/A
P/B
3.48x
P/S
N/A
PEG
N/A
Dividend Yield
N/A
Revenue
N/A
Earnings
N/A
Gross Margin
N/A
Operating Margin
N/A
Profit Margin
N/A
Debt to Equity
0.41
Operating Cash Flow
N/A
Beta
0.38
Next Earnings
N/A
Ex-Dividend
N/A
Next Dividend
N/A
OBIO Overview
Orchestra BioMed Holdings, Inc. operates as a biomedical innovation company. The company's flagship product candidates include BackBeat Cardiac Neuromodulation Therapy (CNT) for the treatment of hypertension; and Virtue Sirolimus AngioInfusion Balloon (SAB) for the treatment of atherosclerotic artery disease. Its products also comprise FreeHold retractors that are minimally invasive surgical device solutions. The company has a strategic collaboration with Medtronic for the development and commercialization of BackBeat CNT for the treatment of hypertension in pacemaker-indicated patients; and a strategic partnership with Terumo Corporation for the development and commercialization of Virtue SAB for the treatment of artery disease. Orchestra BioMed Holdings, Inc. is based in New Hope, Pennsylvania.
Zen Score
–
Industry Average (25)
You've viewed Zen Score for 10/10 free stocks. Upgrade to Premium to see how OBIO scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.
Due Diligence Checks
OBIO is good value based on its book value relative to its share price (3.48x), compared to the US Biotechnology industry average (5.09x)
P/B vs Industry Valuation
OBIO's short-term assets ($119.59M) exceed its short-term liabilities ($11.86M)
Short-term Liabilities Financials
OBIO's short-term assets ($119.59M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
There are 30 more OBIO due diligence checks available for Premium users.
Be the first to know about important OBIO news, forecast changes, insider trades & much more!
OBIO News
Valuation
OBIO price to earnings (PE)
For valuing profitable companies with steady earnings
Company
0x
Industry
13.67x
Market
12.37x
OBIO price to book (PB)
For valuing companies that are loss-making or have lots of physical asset
Company
3.48x
Industry
5.09x
OBIO is good value based... subscribe to Premium to read more.
P/B vs Industry Valuation
OBIO's financial health
Profit margin
Revenue
$915.0k
Net Income
-$12.0M
Profit Margin
-1,316.5%
Assets to liabilities
Assets
$125.9M
Liabilities
$36.4M
Debt to equity
0.41
OBIO's short-term assets ($119.59M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
OBIO's short-term assets ($119.59M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
OBIO's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials
Cash flow
Operating
-$10.5M
Investing
$8.1M
Financing
$86.0k
OBIO vs Biotech Stocks
Orchestra Biomed Holdings Stock FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.